BMS, Isis ink cholesterol drug pact

Bristol-Myers Squibb inked a deal with Isis Pharmaceuticals to collaborate on the discovery, development and commercialization of antisense drugs targeting the gene PCSK9 for cardiovascular disease. PCSK9 helps regulate the amount of cholesterol in the bloodstream. Bristol-Myers Squibb will pay Isis a $15 million upfront and provide $9 million in research funding for three years. Isis will also receive up to $168 million for the achievement of pre-specified development and regulatory milestones for the first drug in the collaboration. 

- see the release for more

Related Articles:
Isis touts positive cholesterol data in LDL study. Report
Exelixis, BMS partner on cholesterol-lowering drugs. Report
Better times ahead for BMS? Report

Suggested Articles

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.